Pot’s not green. The $3.5 billion U.S. cannabis market is emerging as one of the nation’s most power-hungry industries, with the 24-hour demands of thousands of indoor growing sites taxing aging electricity grids and unraveling hard-earned gains in energy conservation.

Nearly two years after recreational pot sales became legal across the state, state tourism officials have continued to downplay Colorado's weed tourism, with some officials going as far as to deny the lure of cannabis culture — against all evidence.

A recent Colorado Tourism Office survey of summer travelers shows 48 percent were influenced by legal recreational pot.

The investment arm of Bank of America, Merrill Lynch, sent out a 45 page equity report last week focused on prospects related to marijuana. Carefully researched, it was an interesting peek at how heavy hitters on Wall Street are starting to view the expanding industry.

GW Pharmaceuticals, which makes drugs derived from the cannabis plant, is scaling up its manufacturing capacity ahead of an expected approval of a new treatment for children with life-threatening epilepsy.

With the cannabis industry booming in states like Colorado, Washington and California, it may be surprising that a new startup has decided to take root in Philadelphia.

It’s possible that there has been no greater contributor to the cultural shift currently occurring around cannabis use in North America than the growing understanding of its medical applications.

Not to be outdone by much larger national retailers, Denver’s cannabis merchants are rolling out Black Friday deals of their own.

A new wave of legal-weed entrepreneurs wants to put the dope in your doppio. And the potential profits from a mashup of coffee and caffeine are, well, high.